NEWS

Avrion Therapeutics elects Gael Hedou as new Chairperson of Board

Avrion Therapeutics AG elects Dr. Gael Hedou, founder and former CEO of Relief Therapeutics Holding AG, as new Chairman of the Board of Directors.
Basel, 2021-01-13 – Avrion Therapeutics AG elects Gael Hedou, founder and former CEO of Relief Therapeutics Holding AG, as new Chairman of the Board of Directors.

Avrion Therapeutics AG (“Avrion” or the “Company”), a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL) focusing on gene therapy for neurodegenerative diseases, announced today the election of Dr. Gael Hedou as the new Chairperson of the Board of Directors. Dr. Hedou is the founder and former CEO of Relief Therapeutics Holding AG. He will empower the activities of Avrion to advance gene therapy solutions for neurodegeneration including preparation of the Company for its next stage of growth, the progression of Avrion’s first product candidate AVR-001 to address Amyotrophic Lateral Sclerosis (ALS), a fatal neuromuscular disorder.

Avrion has developed an innovative gene therapy platform to selectively and safely deliver therapeutic transgenes to discrete cells in the brain, including neurons and astrocytes. The Company is currently fundraising to enable the clinical development of its first gene therapy product candidate AVR-001 to treat ALS patients.

Maximilien Murone, co-founder and CEO at Avrion Therapeutics AG said, “We are thrilled that Gael has joined Avrion both as an investor and as Chairman of our Board. Gael’s experience is a huge strategic asset to our Company. Gael brings not only his track record as biotech entrepreneur, but also a long-standing expertise in project development in neurosciences. This reservoir of knowledge and experience will support the consolidation of Avrion’s pipeline of precision gene therapy solutions for neurodegenerative diseases.”

“I have been extremely impressed by the level of preparedness of the team at Avrion as well as by the sophistication of the science and the robustness of supporting preclinical data. This constitutes a very solid ground on which further developments will be conducted, hopefully leading to new efficacious treatments for ALS patients who live with highly burdensome distress before succumbing to this fatal diease. I would like to express my gratitude to Avrion’s shareholders for the expression of their trust and I can’t wait to play an active part in Avrion’s journey,” said Gael Hedou.

About Avrion Therapeutics AG
Avrion Therapeutics was founded in 2020 based on more than 10 years of research from the Brain Mind Institute and Gene Therapy Platform at the Swiss Federal Institute of Technology Lausanne (EPFL) led by the groups of Dr. Bernard Schneider, Prof. Patrick Aebischer and Prof. Brian McCabe. Avrion’s mission is to develop its first product AVR-001 as a treatment for amyotrophic lateral sclerosis (ALS) in addition to other programs of precision gene therapy solutions for neurodegenerative diseases. Avrion’s exclusive gene therapy technology uses vectors to deliver therapeutic gene sequences to discrete cell types in the central nervous system. Gene therapies can provide benefit through modulation of gene function and typically require a single administration of the treatment. Avrion's first clinical candidate gene therapy product, AVR-001, is preparing to enter IND-enabling studies to treat patients with a form of the motor neuron disease ALS.

avrionhelixbluesmall

AVRION UPDATES